Table of Contents

company-logo

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics Dividend Announcement

• Kymera Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Kymera Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Kymera Therapeutics Dividend History

Kymera Therapeutics Dividend Yield

Kymera Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Kymera Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Kymera Therapeutics Financial Ratios

P/E ratio-23.56
PEG ratio34.40
P/B ratio4.42
ROE-24.96%
Payout ratio0.00%
Current ratio8.55
Quick ratio8.57
Cash Ratio1.66

Kymera Therapeutics Dividend FAQ

Does Kymera Therapeutics stock pay dividends?
Kymera Therapeutics does not currently pay dividends to its shareholders.
Has Kymera Therapeutics ever paid a dividend?
No, Kymera Therapeutics has no a history of paying dividends to its shareholders. Kymera Therapeutics is not known for its dividend payments.
Why doesn't Kymera Therapeutics pay dividends?
There are several potential reasons why Kymera Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Kymera Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Kymera Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Kymera Therapeutics a dividend aristocrat?
Kymera Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Kymera Therapeutics a dividend king?
Kymera Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Kymera Therapeutics a dividend stock?
No, Kymera Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Kymera Therapeutics stocks?
To buy Kymera Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Kymera Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.